NCT06937177ClinicalTrials.gov

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

En reclutamientoAdmite participantes ahora, según el registro.

Contactar con este estudio

En resumen

Fase 2120 participantes buscados26 centros2 países

Categorías

Oncología67%Endocrino y metabólico18%Gastroenterología y hepatología15%

Registrado en 1 registro

ClinicalTrials.govNCT06937177Abrir este registro en ClinicalTrials.govSincronizado hace 2 meses

Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.

La información del ensayo se muestra tal como la publicó el registro, en su idioma original.

¿Le interesa este estudio?

Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

Present: Registered before enrolment beganFirst posted 2025-04-22; recorded start 2025-04-28
Present: Has a defined primary outcomeA primary outcome measure is listed in the record
Present: The primary outcome states a time frameThe primary outcome measure records a time frame
Present: Participants are randomly assignedAllocation is recorded as randomised
Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
Present: Uses blinding (masking)A masking level is recorded in the record
Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
Present: Sponsor has 1 other study in this databaseCounted from the lead sponsor named in the record (Endevica Bio)
Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database

The record lists 1 condition.
Lead sponsor type recorded as: industry.
Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built

Randomised allocation20/20
Participants are randomly allocated between arms
Blinding20/20
Quadruple-blind
Control arm13/15
Placebo / sham control arm
Primary-outcome specificity10/10
Named primary outcome with a defined time frame
Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
Multi-centre8/8
Multi-centre: 26 sites
Data monitoring committee7/7
A data monitoring committee is in place
Prospective registration5/5
Registered before the study start date
Protocol / SAP posted0/5
No protocol or SAP posted to the registry

ScaleSMALL

A small study, international in scope: 120 participants (target), run at 26 sites, across 2 countries.

How this score is built

Enrolment19/40
120 participants (target)
Site count17/25
26 sites
Country count7/15
2 countries
Planned duration8/10
Planned over about 32 months
Sponsor scale1/10
Endevica Bio has led 2 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built

Investigator standing0/100
No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Resumen

This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newly diagnosed, advanced, unresectable colorectal cancer (CRC) or 2) patients with newly diagnosed, advanced, unresectable pancreatic ductal adenocarcinoma (PDAC). Within each cohort, patients will be randomized 1:1:1:1 to receive placebo or one of three different doses of mifomelatide (12.5 mg, 25 mg, or 50 mg). This study is designed to evaluate the effects of different doses of mifomelatide on weight, body composition and BMI. The double-blind (DB) phase will generally begin on the first day of the second cycle of first-line cancer chemotherapy and continue for 12-weeks with the goal of maintaining body weight and muscle mass in patients undergoing chemotherapy relative to control. Upon completion of the DB treatment period, eligible patients may enroll in an optional Open Label Extension (OLE) phase and receive mifomelatide SC 25 mg daily for up to an additional 26 weeks. The purpose of the OLE is to further evaluate long-term safety, tolerability and efficacy of mifomelatide.

Afecciones

Cancer Weight Loss

Elegibilidad

Elegibilidad
Sexo	Todos
Edades	18 Years – Sin máximo
Voluntarios sanos	No

Elegibilidad tal como figura en el registro

Inclusion Criteria: 1. Must be at least 18 years of age. 2. An ECOG performance status of ≤ 2. 3. Life expectancy of ≥ 4 months. 4. Able to eat and digest food normally. Patients with colostomies are allowed. 5. Must meet the following: 1. Newly diagnosed colorectal adenocarcinoma (CRC) or pancreatic ductal adenocarcinoma (PDAC) that is unresectable, locally advanced (i.e., surgery with curative intent is not an option) or metastatic. Note: patients must not have relapsed within 6 months after completing prior treatment for early-stage disease. 2. Determined by the Investigator to be ready to receive their second dose of chemotherapy. 3. Patients currently enrolled and receiving study intervention under Protocol Version 2.0 may be eligible to enroll into Protocol Version 3.0, provided the amended protocol has received all regulatory and ethics approvals and the patient has reviewed and signed the updated consent form prior to any procedures conducted under the amended protocol. Enrollment into the OLE phase must occur ≤14 days following completion of the Week 12 DB visit. 6. Patients must be initiating treatment with one of the following chemotherapy regimens: a) Gemcitabine plus nab-paclitaxel (GNP), Gemcitabine plus capecitabine, NALIRIFOX, FOLFOX, FOLFIRI, or FOLFIRINOX are permitted. These regimens may be administered with or without bevacizumab, other FDA-approved monoclonal antibodies, or other FDA approved agents as clinically indicated for the patient's cancer type. The primary cancer therapy (including dose, schedule, or specific agents) may be modified as medically indicated. 7. Must be able and willing to safely self-inject daily or be injected by a caregiver. 8. Must have evaluable disease by RECIST 1.1. 9. Must have adequate end organ function as defined by: 1. ANC ≥ 1.5 × 10\^9/L 2. Platelets ≥ 100 × 10\^9/L, or adequate as determined by the medical judgement of the investigator; lab may be repeated as needed to rule out initial transient lab abnormality that does not require medical intervention 3. Hemoglobin ≥ 9 g/dL, or adequate as determined by the medical judgement of the investigator; lab may be repeated as needed to rule out initial transient lab abnormality that does not require medical intervention 4. AST and ALT ≤ 3 × ULN; if liver metastases, then ≤ 5 ×ULN; lab may be repeated as needed to rule out initial transient lab abnormality that does not require medical intervention 5. Bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN in the presence of documented Gilbert's Syndrome; lab may be repeated as needed to rule out initial transient lab abnormality that does not require medical intervention 6. Albumin between 3.4 and 5.4 gm/dL or within institutional normal limits, or not considered clinically significant by the investigator; lab may be repeated as needed to rule out initial transient lab abnormality that does not require medical intervention 7. Creatinine clearance ≥ 50 mL/min (calculated by Cockcroft and Gault equation; lab may be repeated as needed to rule out initial transient lab abnormality that does not require medical intervention 8. Normal hemoglobin A1c levels based on institutional normal limits, or not considered clinically significant by the investigator; lab may be repeated as needed to rule out initial transient lab abnormality that does not require medical intervention 10. NT-Pro-BNP and Troponin (TnI or TnT) are within normal limits or not considered to be clinically significant by the investigator; lab may be repeated as needed to rule out initial transient lab abnormality that does not require medical intervention 11. If a female of childbearing capability, must have a negative pregnancy test within 2 weeks of starting treatment. 12. Fertile men and women must agree to use adequate contraception for the duration of the trial. 13. Willing and able to sign informed consent. 14. Additional cohort-specific inclusion criteria: 1. CRC Cohort i. Must have a BMI ≤ 29 kg/m\^2. 2. PDAC Cohort i. Cachexia defined by Fearon Criteria of weight loss ii. Patients with diagnosed exocrine pancreatic insufficiency (EPI) must be receiving prescription pancreatic enzyme replacement therapy (PERT) per standard of care (SOC). Exclusion Criteria 1. Patients receiving second line or later systemic treatment 2. Patients with swallowing abnormalities, malabsorption syndromes, short or inflammatory bowel syndromes, or other conditions that in the Investigator's opinion could impair food consumption or metabolism. 3. History of weight loss surgery including gastric stapling, or bypass surgery. 4. Currently using any new agent prescribed to increase appetite or otherwise affect weight (increase or decrease). a) Antiemetics or other standard of care medications for treatment or prevention of nausea and vomiting are acceptable. * Patients with newly prescribed glucocorticoids for less than four weeks at the time of Screening and whose weight is not yet stable are excluded. Stable (dose unchanged for 4 weeks or more) and low dose (\<5 mg) corticosteroids are permissible, as are inhaled corticosteroids. * Drugs like Olanzapine are allowed only when used as an antiemetic, as needed (PRN). If used to treat cachexia, drugs like Olanzapine are not allowed. 5. Chronic and ongoing use of corticosteroids at a dose of ≥5 mg of prednisone or equivalent per day. 6. History of bulimia or anorexia. 7. Pregnancy, lactation, or plans to become pregnant. 8. History of another malignancy except basal cell carcinoma of the skin, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy that has previously undergone potentially curative therapy. 9. Concurrent participation in any other clinical trial. 10. Patients with known brain or CNS metastases. 11. Impaired cardiac function or significant cardiac issues including, but not limited to, any of the following: 1. Greater than class II NYHA congestive heart failure 2. Congenital long QT syndrome 3. QTc \> 470 msec (as calculated by institution standards) confirmed by two ECGs ≥ 1-minute apart (QTc interval corrected using \[Fridericia's formula \[QTcF\]) 4. Unstable angina pectoris 5. Acute myocardial infarction ≤ 6 months prior to study entry 12. Known hypersensitivity to mifomelatide or its formulation. 13. History of allergic or anaphylactic reaction to any chemotherapeutics. 14. Known diagnosis of HIV infection (HIV testing is not mandatory). Patients with a history of HIV regardless of viral load are excluded. 15. Active infection with Hepatitis B, Hepatitis C, or active systemic viral disease or active severe infection. 16. Unwilling or unable to comply with the protocol. 17. Any condition that, in the Investigator's opinion, would impair the patients' ability to participate in this study. 18. Additional cohort-specific exclusion criteria 1. CRC cohort i. Unintentional weight loss ≥ 10% of usual body weight in 4 months prior to Screening 2. PDAC cohort i. Neuroendocrine (carcinoid, islet cell) of acing pancreatic carcinoma ii. Unintentional weight loss ≥ 20% of usual body weight in 4 months prior to Screening

Elegibilidad en frases sencillas

Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.

Diseño del estudio

Diseño del estudio
Tipo de estudio	De intervención
Fase	Fase 2
Asignación	Aleatorizado
Modelo de intervención	PARALLEL
Propósito principal	TREATMENT
Enmascaramiento	QUADRUPLE (4)
Inscripción	120 participantes buscados

Patrocinador y colaboradores

Endevica Bio Patrocinador

Grupos e intervenciones

Placebo administered subcutaneously daily for 12 weeksPLACEBO_COMPARATOR
Mifomelatide (TCMCB07) 12.5 mg administered subcutaneously daily for 12 weeksEXPERIMENTAL
Mifomelatide (TCMCB07) 25 mg administered subcutaneously daily for 12 weeksEXPERIMENTAL
Mifomelatide (TCMCB07) 50 mg administered subcutaneously daily for 12 weeksEXPERIMENTAL

Intervenciones

Fármaco Placebo
Matching placebo
Fármaco TCMCB07
TCMCB07 is will be provided in single-use vials for subcutaneous administration

Variables de resultado

Variable de resultado principal
Incidence of abnormalities in vital signs
Plazo From enrollment to the end of the 12 week dosing period
Variable de resultado principal
Change from baseline in body weight
Plazo At 12 weeks of treatment
Variable de resultado principal
Incidence and severity of adverse events (AEs), AESIs, and SAEs
Plazo From enrollment to the end of the 12 week dosing period
Variable de resultado principal
Incidence of abnormalities in laboratory evaluations
Plazo From enrollment to the end of the 12 week dosing period
Variable de resultado secundaria
Change from baseline in total score of Functional Assessment of Anorexia/Cachexia Therapy-anorexia-related symptoms scale (FAACT-5IASS)
FAACT-5IASS scores items using a 5-point scale (0-4).Higher scores are associated with a higher health-related quality of life.
Plazo At 12 weeks of treatment
Variable de resultado secundaria
Change from baseline in the anorexia and cachexia subscore of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT-ACS) questionnaire
FAACT-ACS score sums 12 items; both use a 5-point scale (0-4).Higher scores are associated with a higher health-related quality of life.
Plazo At 12 weeks of treatment
Variable de resultado secundaria
Change from baseline in BMI
Weight and height will be combined to report BMI in kg/m\^2
Plazo At 12 weeks of treatment
Variable de resultado secundaria
Change from baseline in body weight
Plazo At 8 weeks of treatment
Variable de resultado secundaria
Change from baseline in BMI
Weight and height will be combined to report BMI in kg/m\^2
Plazo At 8 weeks of treatment
Variable de resultado secundaria
Change from baseline in body weight
Plazo At 4 weeks of treatment
Variable de resultado secundaria
Change from baseline in BMI
Weight and height will be combined to report BMI in kg/m\^2
Plazo At 4 weeks of treatment
Variable de resultado secundaria
Change from baseline in the FAACT questionnaire comprising the general quality of life FAACT-G and FAACT-ACS anorexia and cachexia related subscale
FAACTG and FAACT ACS score score items using a 5-point scale (0-4).Higher scores are associated with a higher health-related quality of life.
Plazo At 12 weeks of treatment
Variable de resultado secundaria
Change from baseline in total score and subscores of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Scoring ranges from 0 to 100 with 0 being the worst possible score and 100 being the best.
Plazo At 12 weeks of treatment
Otra variable de resultado
Blood levels of mifomelatide
Plasma concentrations of mifomelatide collected at prespecified sampling timepoints
Plazo From enrollment to the end of the 12 week treatment period
Otra variable de resultado
Immunogenicity profile of mifomelatide
Plazo From enrollment to the end of the 12 week treatment period
Otra variable de resultado
Change from baseline in lean mass
Determined by medical imaging
Plazo From enrollment to the end of the 12 week treatment period
Otra variable de resultado
Change from baseline in fat mass
Determined by medical imaging
Plazo From enrollment to the end of the 12 week treatment period
Otra variable de resultado
Change from baseline in tumor burden
To determine the response rate by RECIST 1.1 criteria
Plazo At 12 weeks of treatment
Otra variable de resultado
Effect of mifomelatide on chemotherapy relative dose intensity
Comparison of actual dose intensity ratio versus expected chemotherapy dose intensity ratio between mifomelatide and placebo groups
Plazo From enrollment to the end of 12 week treatment period
Otra variable de resultado
Effect of mifomelatide on time-to-deterioration (TTD) in body weight
Time from first dose of study treatment to first clinically meaningful worsening from baseline appetite score (defined as a 4-point decrease in FAACT-ACS score).
Plazo From enrollment to the end of 12 week treatment period
Otra variable de resultado
Effect of mifomelatide on overall survival at predefined timepoints including Week 12 in the DB and 6 and 9 months in the OLE
Landmark overall survival rates, defined as the proportion of patients alive at each specified timepoint (Week 12, Month 6 and Month 9) following the first dose of study intervention.
Plazo From enrollment to the end of 12 week treatment period, Month 6 and Month 9 in OLE
Otra variable de resultado
Characterize disease progression outcomes in study patients
Progression-free survival (PFS), defined as the time from first documentation of disease progression or death from any cause, whichever occurs first (including OLE where applicable).
Plazo From enrollment through Week 26 in OLE where applicable
Otra variable de resultado
Overall survival
Overall survival (OS), defined as the time from first dose of study drug in the DB phase to death from any cause (including OLE where applicable).
Plazo From enrollment to death from any cause (including OLE where applicable)

Fechas

Fechas
Fecha de inicio	28 de abril de 2025 (real)
Finalización principal	1 de octubre de 2027 (estimada)
Finalización	1 de diciembre de 2027 (estimada)
Primera publicación	22 de abril de 2025 (real)
Última actualización	15 de julio de 2026
Resultados publicados	No indicado en el registro
Estado verificado por última vez	julio de 2026

Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.

Ubicaciones

22 centros están en reclutamiento

Canada

Canada
Centro	Ciudad	Estado o región	Estado
Cross Cancer Institute	Edmonton	Alberta	En reclutamiento

United States

United States
Centro	Ciudad	Estado o región	Estado
Piedmont Healthcare Inc.	Atlanta	Georgia	En reclutamiento
Medical University of South Carolina	Charleston	South Carolina	Aún no recluta
University of Virginia	Charlottesville	Virginia	En reclutamiento
Northwestern University - Robert H. Lurie Comprehensive Cancer Center	Chicago	Illinois	Aún no recluta
Life Clinical Trials	Coral Springs	Florida	En reclutamiento
Karmanos Cancer Center	Detroit	Michigan	En reclutamiento
Duke University Medical Center	Durham	North Carolina	En reclutamiento
Bioresearch Partners	Hialeah	Florida	En reclutamiento
Hope and Healing Cancer Services	Hinsdale	Illinois	Aún no recluta
Lumi Research	Kingwood	Texas	En reclutamiento
Laguna Clinical Research Associates	Laredo	Texas	En reclutamiento
NHO Revive Research Institute	Lincoln	Nebraska	En reclutamiento
Cedars-Sinai Medical Center	Los Angeles	California	En reclutamiento
D&H Cancer Research Center	Margate	Florida	En reclutamiento
Baptist Clinical Research	Memphis	Tennessee	En reclutamiento
Mt. Sinai Cancer Center	Miami Beach	Florida	En reclutamiento
Vanderbilt-Ingram Cancer Center	Nashville	Tennessee	Aún no recluta
NYU Langone Health Perlmutter Cancer Center	New York	New York	En reclutamiento
Hightower Clinical	Oklahoma City	Oklahoma	En reclutamiento
Nebraska Cancer Specialists	Omaha	Nebraska	En reclutamiento
UCLA Medical Center	Santa Monica	California	En reclutamiento
Orchard Healthcare Research	Skokie	Illinois	En reclutamiento
BRCR Global	Tamarac	Florida	En reclutamiento
Arizona Clinical Research Center	Tucson	Arizona	En reclutamiento
Cancer Centers of Kansas	Wichita	Kansas	En reclutamiento

Documentos del estudio

No hay documentos enlazados en este registro.

Cambios a lo largo del tiempo

No se han registrado cambios desde que incorporamos este registro por primera vez.

Se registra un cambio cada vez que el patrocinador actualiza el registro. El estado, las fechas, la inscripción y los centros aparecen aquí a medida que cambian.

Registro: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT06937177